Loading organizations...
Key people at Nygen Analytics AB.
Nygen Analytics AB develops an AI-native interpretation layer specifically for single-cell omics data. Its core offering surfaces biological signals often missed by conventional analysis, providing deeper insights and faster clarity for researchers. The company's platform includes CyteType, a structured AI reasoning engine for confidence-scored and evidence-backed cell identity assignment, and ScarfWeb, a distributed, secure, browser-native solution for intuitive secondary analysis of complex genomic data. This technology is purpose-built, covering computation, annotation, and interpretation within single-cell biology workflows.
The company was founded in 2022 by Parashar Dhapola, who serves as CEO, and Göran Karlsson, both holding PhDs. Their foundational insight stemmed from the need for more affordable and accessible solutions to analyze increasingly complex genomics data. Dhapola, with his background in computational biology from Lund University and expertise across genomics, machine learning, and cloud technologies, laid the groundwork for the ScarfWeb platform, enabling professionals to derive meaningful results without extensive computational infrastructure.
Nygen Analytics serves a broad scientific community, empowering discovery at leading research institutions and within pharmaceutical development across various stages, including biomarker identification, translational research, and cell therapy. The company's vision centers on democratizing powerful single-cell technology, thereby pushing programs beyond mere data description into tangible discovery. Its long-term goal is to translate biological findings into traceable, auditable, and actionable insights to address significant challenges in drug discovery.
Nygen Analytics AB is a Swedish biotech software startup founded in 2022, specializing in a cloud-based, no-code platform for single-cell genomics data analysis, visualization, and management.[1][3][7] It serves biotechnology, pharmaceutical industries, academia, and research facilities by enabling non-programmers to interpret complex single-cell omics datasets, accelerating drug discovery and therapeutic development through AI-powered tools like Nygen Analytics, Nygen Database, and LLM-augmented Nygen Insights.[1][3][6] The company has raised $930K total, including a recent €800K from SmiLe Inject Capital and a 1M SEK Vinnova grant for AI-driven cancer immunotherapy models, demonstrating strong early growth in the precision medicine space.[1][5][6]
Nygen Analytics was founded in 2022 in Lund, Sweden, at Medicon Village, a key biopharma innovation hub fostering collaborations among research institutions, biotech firms, and pharma giants.[1][3] The founding team blends deep expertise: a computational biologist with 100+ citations and GitHub stars in single-cell analysis; a single-cell scientist (Associate Professor) who built Sweden's first single-cell facility, secured €3M+ in grants, and launched clinical trials from single-cell data; a single-cell profiling pioneer and serial genomics founder; and a cybersecurity founder acquired by a Fortune 100 company, now active as an investor.[3] The idea emerged from addressing the explosion of single-cell data in drug discovery, with early traction via academic partnerships (10+ universities), a patent-pending algorithm portfolio, and breakthroughs like a 2025 preprint enabling a Phase 1 trial.[3][6]
Nygen rides the single-cell omics boom, where datasets are exploding due to cheaper sequencing, fueling precision medicine and AI-driven drug discovery amid a shift to agentic biology tools.[3][6] Timing aligns with post-2022 AI advancements (e.g., LLMs for biology) and Europe's life sciences push, amplified by hubs like Medicon Village and funds like SmiLe Inject Capital.[1][3][5] Market tailwinds include rising demand for cost-effective analysis in cancer immunotherapy and personalized treatments, where Nygen's predictive models cut development time.[6] It influences the ecosystem by bridging experimental wet-lab work with computational insights, enabling faster target identification and clinical translation, as seen in Swedish-US collaborations advancing global health innovations.[3][6]
Nygen is poised to lead AI-augmented single-cell analysis, expanding its platform into a full autonomous engine for perturbation prediction and disease modeling, building on Vinnova-funded immunotherapy work.[3][6] Trends like multi-modal omics integration and agent-driven analytics will propel growth, potentially attracting Series A funding amid biotech's AI pivot. Its influence may evolve from tool provider to ecosystem enabler, powering more trials and partnerships—transforming how researchers turn raw genomics data into therapies, much like its origins democratized complex analysis for everyday biologists.[3][6]
Key people at Nygen Analytics AB.
